CY1125175T1 - Παραγωγα πολυμυξινης και η χρηση τους σε συνδυασμενη θεραπεια μαζι με διαφορετικα αντιβιοτικα - Google Patents

Παραγωγα πολυμυξινης και η χρηση τους σε συνδυασμενη θεραπεια μαζι με διαφορετικα αντιβιοτικα

Info

Publication number
CY1125175T1
CY1125175T1 CY20221100299T CY221100299T CY1125175T1 CY 1125175 T1 CY1125175 T1 CY 1125175T1 CY 20221100299 T CY20221100299 T CY 20221100299T CY 221100299 T CY221100299 T CY 221100299T CY 1125175 T1 CY1125175 T1 CY 1125175T1
Authority
CY
Cyprus
Prior art keywords
combination therapy
different antibiotics
polymyxin derivatives
iii
compounds
Prior art date
Application number
CY20221100299T
Other languages
Greek (el)
English (en)
Inventor
Pamela Brown
Michael Dawson
Mona SIMONOVIC
Steven Boakes
Esther DUPERCHY
Steven James Stanway
Antoinette Wilson
Stephen Frederick Moss
Original Assignee
Spero Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201404301A external-priority patent/GB201404301D0/en
Priority claimed from GB201421019A external-priority patent/GB201421019D0/en
Application filed by Spero Therapeutics, Inc. filed Critical Spero Therapeutics, Inc.
Publication of CY1125175T1 publication Critical patent/CY1125175T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
    • C07K7/62—Polymyxins; Related peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CY20221100299T 2014-03-11 2022-04-20 Παραγωγα πολυμυξινης και η χρηση τους σε συνδυασμενη θεραπεια μαζι με διαφορετικα αντιβιοτικα CY1125175T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201404301A GB201404301D0 (en) 2014-03-11 2014-03-11 Compounds and combinations
GB201421019A GB201421019D0 (en) 2014-11-26 2014-11-26 Compounds

Publications (1)

Publication Number Publication Date
CY1125175T1 true CY1125175T1 (el) 2024-12-13

Family

ID=52823596

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20221100299T CY1125175T1 (el) 2014-03-11 2022-04-20 Παραγωγα πολυμυξινης και η χρηση τους σε συνδυασμενη θεραπεια μαζι με διαφορετικα αντιβιοτικα

Country Status (21)

Country Link
US (3) US20170073373A1 (cg-RX-API-DMAC7.html)
EP (1) EP3116897B1 (cg-RX-API-DMAC7.html)
JP (1) JP6785659B2 (cg-RX-API-DMAC7.html)
KR (2) KR20160135739A (cg-RX-API-DMAC7.html)
CN (1) CN106232617B (cg-RX-API-DMAC7.html)
AU (1) AU2015228898B2 (cg-RX-API-DMAC7.html)
CA (1) CA2940455C (cg-RX-API-DMAC7.html)
CY (1) CY1125175T1 (cg-RX-API-DMAC7.html)
DK (1) DK3116897T3 (cg-RX-API-DMAC7.html)
ES (1) ES2910072T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20220387T1 (cg-RX-API-DMAC7.html)
IL (1) IL247243B (cg-RX-API-DMAC7.html)
LT (1) LT3116897T (cg-RX-API-DMAC7.html)
MX (1) MX359104B (cg-RX-API-DMAC7.html)
PL (1) PL3116897T3 (cg-RX-API-DMAC7.html)
PT (1) PT3116897T (cg-RX-API-DMAC7.html)
RS (1) RS63138B1 (cg-RX-API-DMAC7.html)
RU (1) RU2740190C2 (cg-RX-API-DMAC7.html)
SI (1) SI3116897T1 (cg-RX-API-DMAC7.html)
TW (1) TWI709575B (cg-RX-API-DMAC7.html)
WO (1) WO2015135976A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2855916A1 (en) * 2011-11-18 2013-05-23 Novacta Biosystems Limited Polymyxin derivatives
EP3126376B1 (en) 2014-04-01 2024-08-21 Monash University Polymyxin derivatives as antimicrobial compounds
CN107108699A (zh) 2014-11-26 2017-08-29 新药物许可控股有限公司 化合物
EP3233889B1 (en) 2014-12-16 2022-07-06 Shanghai MicuRx Pharmaceutical Co., Ltd. Antimicrobial polymyxins for treatment of bacterial infections
CN105030744B (zh) * 2015-07-09 2019-04-19 广州英赛特生物技术有限公司 取代苯胍衍生物作为多粘菌素类抗生素增效剂的应用
CN108350034B (zh) * 2015-09-29 2022-03-11 莫纳什大学 抗微生物的多黏菌素衍生的化合物
JP6744622B2 (ja) * 2016-06-16 2020-08-19 学校法人上智学院 ピペリジン化合物の製造方法
JP2021501783A (ja) * 2017-11-02 2021-01-21 ザ ユニバーシティー オブ クイーンズランド ペプチド抗生物質
LT3810633T (lt) 2018-06-25 2024-01-10 Spero Therapeutics, Inc. Junginiai
CN111690040A (zh) * 2019-03-12 2020-09-22 上海来益生物药物研究开发中心有限责任公司 多粘菌素衍生物、其制备方法和应用
CN115298198A (zh) 2020-01-21 2022-11-04 上海盟科药业股份有限公司 用于肾相关癌症靶向治疗的新型化合物和组合物
TW202233649A (zh) 2020-11-06 2022-09-01 美商斯佩羅治療學股份有限公司 化合物
CN120699105B (zh) * 2025-08-19 2025-11-21 中国药科大学 一种氘代抗菌肽及其组合物和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060004185A1 (en) * 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
SI2057185T1 (sl) * 2006-08-11 2016-10-28 Northern Antibiotics Oy Derivati polimiksina in njihove uporabe
WO2010075416A1 (en) * 2008-12-23 2010-07-01 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
CN101851270A (zh) * 2009-04-03 2010-10-06 梁浩 一种多粘菌素衍生物及其制备方法
US8415307B1 (en) * 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
WO2012168820A1 (en) * 2011-06-08 2012-12-13 Pfizer Inc. Polymyxin derivatives useful as antibacterial agents
CA2855916A1 (en) * 2011-11-18 2013-05-23 Novacta Biosystems Limited Polymyxin derivatives
PT2999711T (pt) * 2013-05-22 2022-07-29 Spero Therapeutics Inc Derivados de polimixina e a sua utilização em terapia de combinação em conjunto com antibióticos diferentes

Also Published As

Publication number Publication date
TWI709575B (zh) 2020-11-11
HRP20220387T1 (hr) 2022-05-27
TW201617362A (zh) 2016-05-16
EP3116897A1 (en) 2017-01-18
WO2015135976A1 (en) 2015-09-17
KR20160135739A (ko) 2016-11-28
MX359104B (es) 2018-09-14
MX2016011682A (es) 2017-04-27
US20210221848A1 (en) 2021-07-22
DK3116897T3 (da) 2022-03-28
RS63138B1 (sr) 2022-05-31
EP3116897B1 (en) 2022-03-02
JP2017510570A (ja) 2017-04-13
PT3116897T (pt) 2022-04-07
CN106232617B (zh) 2022-06-24
CA2940455C (en) 2023-03-21
SI3116897T1 (sl) 2022-06-30
RU2016139978A (ru) 2018-04-13
ES2910072T3 (es) 2022-05-11
RU2016139978A3 (cg-RX-API-DMAC7.html) 2018-10-17
AU2015228898A1 (en) 2016-10-20
IL247243B (en) 2020-04-30
CN106232617A (zh) 2016-12-14
US20230322858A1 (en) 2023-10-12
CA2940455A1 (en) 2015-09-17
KR20230152779A (ko) 2023-11-03
US20170073373A1 (en) 2017-03-16
IL247243A0 (en) 2016-09-29
LT3116897T (lt) 2022-05-10
PL3116897T3 (pl) 2022-05-30
RU2740190C2 (ru) 2021-01-12
AU2015228898B2 (en) 2018-11-15
JP6785659B2 (ja) 2020-11-18

Similar Documents

Publication Publication Date Title
CY1125175T1 (el) Παραγωγα πολυμυξινης και η χρηση τους σε συνδυασμενη θεραπεια μαζι με διαφορετικα αντιβιοτικα
CY1123598T1 (el) Μακροκυκλικα πεπτιδια χρησιμα ως ανοσοδιαμορφωτες
CL2019001874A1 (es) Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos.
CY1122065T1 (el) Ενωσεις αλκυλ-αμιδο-υποκατεστημενου πυριδυλιου χρησιμες ως διαμορφωτες των αποκρισεων il-12, il-23 και/η ιfναλφα
CY1121701T1 (el) Οργανικες ενωσεις μονοβακταμης για την αντιμετωπιση βακτηριακων λοιμωξεων
HUE057426T2 (hu) Heteroaril-szubsztituált béta-hidroxietilamin-származékok magas vécukorszint kezelésére való alkalmazásra
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
CY1121384T1 (el) Συνδυαστικη θεραπεια για την αγωγη ανθεκτικων βακτηριακων λοιμωξεων
MX2020002823A (es) Fluorofenil beta-hidroxietilaminas y su uso en el tratamiento de la hiperglucemia.
CY1122805T1 (el) Ενωσεις και μεθοδοι για την αγωγη βακτηριακων λοιμωξεων
GT201500088A (es) Derivados de 5-fenoxi-3h-pirimidin-4-ona y su uso como inhibidores de la transcriptasa inversa del vih
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
UY34278A (es) Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades
CY1120607T1 (el) Παραγωγα ισοϊνδολινης για χρηση στη θεραπεια μιας ιικης μολυνσης
CY1122818T1 (el) Παραγωγα 3-((ετερο-)αρυλ)-αλκυλ-8-αμινο-2-οξο-1,3-διαζα- σπε1ρο-[4.5]-δεκανιου
MX381911B (es) Derivados heterociclicos y uso de los mismos.
CY1116186T1 (el) Μακροκυκλικες ενωσεις και μεθοδοι για την παραγωγη τους
IL271863B (en) Compounds and use thereof for the treatment of microbial infections
CY1122923T1 (el) Παραγωγα 3-((ετερο-)αρυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου
CL2015003019A1 (es) Derivados biaromáticos antibacterianos
CY1122882T1 (el) Παραγωγα 3-(καρβοξυαιθυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου
BR112017026061A2 (pt) composto, uso de um composto, e, método de tratamento de uma infecção viral
CY1122892T1 (el) Παραγωγα 3-(καρβοξυμεθυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου
CY1122971T1 (el) Ενωσεις διυδροπυριμιδιν-2-ονης και ιaτρικη χρηση αυτων
EA201691412A1 (ru) Гидроксиформамидные производные и их применение